BioSpace News Archive

Lone Star Bio

Nanoscope Therapeutics CEO Sulagna Bhattacharya Elected to BIO Emerging Companies Section Governing Board

Nanoscope Therapeutics Inc., a late clinical-stage ocular gene therapy company, today announced the election of CEO Sulagna Bhattacharya to the Biotechnology Innovation Organization (BIO) Emerging Companies Section Governing Board.

February 17, 2022

·

2 min read

MedHub announces AutocathFFRTM pivotal validation trial data accepted for late-breaking oral presentation and poster at the upcoming CRT22 conference

MedHub., a privately held medical device company focused on improving and simplifying cardiac care by replacing risky and costly invasive procedures with AI image-based tools, today announced that the results of the pivotal validation trial of Medhub’s AutocathFFR™ system were accepted as a late-breaking addition to the CRT 2022 conference.

February 17, 2022

·

2 min read

Drug Development

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers

KAHR, today announced that the first patient has been dosed in a Phase 1b clinical trial of DSP107.

February 17, 2022

·

5 min read

Drug Development

Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium

Alkermes plc (Nasdaq: ALKS) today presented new data from the ongoing phase 1/2 ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the company’s novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy.

February 17, 2022

·

6 min read

Business

Lyra Therapeutics Appoints Harlan W. Waksal, MD, as Executive Chairman

Lyra Therapeutics today announced the appointment of Harlan W. Waksal MD, as Executive Chairman.

February 17, 2022

·

7 min read

Business

Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on the Company’s business and pipeline.

February 17, 2022

·

26 min read

Business

Remix Therapeutics Enters Collaboration with Janssen to Advance Small Molecule Therapeutics Using REMaster Drug Discovery Platform to Modulate RNA Processing

Remix Therapeutics today announced a strategic collaboration with Janssen Pharmaceutica NV for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix’s REMaster drug discovery platform.

February 17, 2022

·

2 min read

New Scoring Sheath Delivers Low Pressure Angioplasty Treatment in Calcified Arteries

Transit Scientific announced continued success with its XO Score Sheath Platform to treat highly-stenosed cardiovascular lesions using low pressure peripheral transluminal angioplasty (PTA).

February 17, 2022

·

1 min read

Drug Development

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Supplemental Biologics License Application for Breyanzi

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma.

February 17, 2022

·

17 min read

Business

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its fourth quarter and full year 2021 results.

February 17, 2022

·

34 min read